Study Stopped
Enrollment Goals not met
An Evaluation of the Ability to Train Established Glaucoma Patients Who Have Difficulty in Drop Instillation
A Prospective Evaluation of the Effect of Training on Eye Drop Administration in Glaucoma Subjects Who Have Difficulties Properly Instilling Eye Drops
1 other identifier
observational
18
1 country
1
Brief Summary
This is a prospective, observational, single-center study. Patients with at least 3 months of experience using topical medications for glaucoma and who state that they administer their own eye drops will be recruited. Subjects will be videotaped instilling a sterile artificial eye drop, will be identified at the time of a regularly scheduled exam. If the patient can get a drop onto the eye and also not touch their lids or ocular surface with the eye drop bottle, the subject will be thanked but not enrolled. All other patients who agree to participate will be enrolled. Upon completion of videotaped instillation of an eye drop, each enrolled patient will be shown a video demonstrating an instillation technique and will be given an instructional handout highlighting a proper drop instillation technique. If necessary, an instillation technique will be demonstrated to them by an investigator or trained personnel. A patient will be identified as properly instilling a drop if they satisfy the following criteia: They are able to instill one (and only one) drop to the ocular surface or lower fornix without allowing the bottle touch the adnexa, eyelid, eye lashes or eye. All patients routinely return between 3 and 6 months. At this regularly scheduled visit,the investigator or trained personnel would direct the patient to instill an eye drop into the study eye.Additionally, the short glaucoma self-efficacy questionnaire will be re-administered. All of the video-recordings of participants' eye drop instillation techniques will be reviewed and assessed using a standard checklist. Their ability to administer an eye drop after training will be compared to baseline.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Oct 2012
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2012
CompletedFirst Submitted
Initial submission to the registry
October 25, 2012
CompletedFirst Posted
Study publicly available on registry
November 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2015
CompletedApril 12, 2017
April 1, 2017
2.7 years
October 25, 2012
April 11, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Ability to administer an eye drop according to our criteria, as outlined in our study summary.
6 months
Eligibility Criteria
Private Ophthalmology Office (Specialty-Glaucoma)
You may qualify if:
- Patients aged 18 years or older
- Patients currently using topical ocular antihypertensive medications at the time of enrollment in at least one eye, and who have been using these drops consistently for a period of at least three months prior to enrollment.
- Patients with primary open angle glaucoma, pigmentary glaucoma, exfoliation glaucoma, ocular hypertension, normal-tension glaucoma, neovascular glaucoma, uveitic glaucoma and chronic narrow angle glaucoma.
- Patients CAN be enrolled even if they have co-existing morbidities such as Parkinson's Disease or arthritis
You may not qualify if:
- Patients who do not instill their own eye drops
- Patients who are not expected to still be using topical antihypertensive medications at the time of study follow-up
- Patients with no light perception vision
- Patients with a history of adverse reaction to artificial tears or any component of artificial tears
- Patients who have a typical follow-up period of greater than 6 months
- Patients who have not completed a Humphrey Visual Field C24-2 or C10-2 within 7 months of enrollment or study exit.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Alan L. Robin, MD, PA
Baltimore, Maryland, 21209, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Adam C LePosa, OD
Alan L. Robin, MD, PA
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDIV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Adam C. LePosa, O.D
Study Record Dates
First Submitted
October 25, 2012
First Posted
November 1, 2012
Study Start
October 1, 2012
Primary Completion
June 1, 2015
Study Completion
June 1, 2015
Last Updated
April 12, 2017
Record last verified: 2017-04